An injectable form of HIV pre-exposure prophylaxis (PrEP) developed by GSK's ViiV Healthcare unit will be offered by the NHS in England and Wales, ending a disparity in access within the UK.
Sanofi been found to be in breach of the UK pharma industry's code of practice over a newspaper article in which it compared its respiratory syncytial virus (RSV) drug Beyfortus with a Pfizer rival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results